NASDAQ
Skye Bioscience, Inc. (SKYE)
♥ 609 Thanks from members
Skye Bioscience faces intense scrutiny and negative equity risks following terminated nimacimab R&D and suboptimal trials, though a pending merger with Redx Pharma to form Fibrx Therapeutics and a $125 million financing lifeline offer a speculative path forward.